Current concepts on antiplatelet therapy: Focus on the novel thienopyridine and non-thienopyridine agents

Advances in Hematology

Volumn 2010, Issue , 2010, Pages

  Bhindi, R ^d   Testa, L ^a   Biondi Zoccai, G G L ^b   Valgimigli, M ^c   Latini, R A ^a   Pizzocri, S ^a   Lanotte, S ^a   Laudisa, M L ^a   Brambilla, N ^a   Ward, M R ^d   Figtree, G A ^d   Bedogni, F ^a  

^a ISTITUTO CLINICO SANT'AMBROGIO   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANGRELOR; CLOPIDOGREL; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL PRACTICE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; METABOLIC ACTIVATION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; THROMBOCYTE ACTIVATION;

EID: 79251574325     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2010/595934     Document Type: Review

References (48)

1. Kastrati A., Schmig A., Schmig E., Are we making efficient use of clopidogrel? European Heart Journal 2004 25 6 454 456
2. Yusuf S., Zhao F., Mehta S. R., Chrolavicius S., Tognoni G., Fox K. K., Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation New England Journal of Medicine 2001 345 7 494 502
3. Gent M., A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 1996 348 9038 1329 1339
4. Fox K., Alonso Garcia M. A., Ardissino D., Buszman P., Camici P. G., Crea F., Daly C., De Backer G., Hjemdahl P., Lopez-Sendon J., Marco J., Morais J., Pepper J., Sechtem U., Simoons M., Thygesen K., Guidelines on the management of stable angina pectoris: executive summarythe Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology European Heart Journal 2006 27 11 1341 1381
5. ACC/AHA,. Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) Developed in Collaboration With the Canadian Cardiovascular Society, 2008, http://www.cardiosource.com/
6. ACC/AHA,. Guideline Update for the Management of Patients With Unstable Angina and NonST-Segment Elevation Myocardial Infarction A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina), http://ww.cardiosource.com/
7. Smith S. C. Jr. , Feldman T. E., Hirshfeld J. W. Jr. , Jacobs A. K., Kern M. J., King S. B. III, Morrison D. A., O'Neill W. W., Schaff H. V., Whitlow P. L., Williams D. O., Antman E. M., Adams C. D., Anderson J. L., Faxon D. P., Fuster V., Halperin J. L., Hiratzka L. F., Hunt S. A., Nishimura R., Ornato J. P., Page R. L., Riegel B., ACC/AHA/SCAI 2005 guideline update for percutaneous coronary interventionsummary article: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention) Catheterization and Cardiovascular Interventions 2006 67 1 87 112
8. Angiolillo D. J., Alfonso F., Clopidogrel-statin interaction: myth or reality? Journal of the American College of Cardiology 2007 50 4 296 298
9. O'Donoghue M., Wiviott S. D., Clopidogrel response variability and future therapies: clopidogrel: does one size fit all? Circulation 2006 114 22 e600 e606
10. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., Novikov I., Pres H., Savion N., Varon D., Hod H., Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 2004 109 25 3171 3175
11. Bliden K. P., DiChiara J., Tantry U. S., Bassi A. K., Chaganti S. K., Gurbel P. A., Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? Journal of the American College of Cardiology 2007 49 6 657 666
12. Geisler T., Langer H., Wydymus M., Ghring K., Zrn C., Bigalke B., Stellos K., May A. E., Gawaz M., Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation European Heart Journal 2006 27 20 2420 2425
13. Collet J.-P., Hulot J.-S., Pena A., Villard E., Esteve J.-B., Silvain J., Payot L., Brugier D., Cayla G., Beygui F., Bensimon G., Funck-Brentano C., Montalescot G., Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study The Lancet 2009 373 9660 309 317
14. Simon T., Verstuyft C., Mary-Krause M., French registry of acute ST-elevation and non-ST-elevation myocardial infarction (FAST-MI) investigators. Genetic determinants of response to clopidogrel and cardiovascular events The New England Journal of Medicine 2009 360 4 636 675
15. Mega J. L., Close S. L., Wiviott S. D., Shen L., Hockett R. D., Brandt J. T., Walker J. R., Antman E. M., Macias W., Braunwald E., Sabatine M. S., Cytochrome P-450 polymorphisms and response to clopidogrel New England Journal of Medicine 2009 360 4 354 362
16. Wiviott S. D., Braunwald E., McCabe C. H., Montalescot G., Ruzyllo W., Gottlieb S., Neumann F.-J., Ardissino D., De Servi S., Murphy S. A., Riesmeyer J., Weerakkody G., Gibson C. M., Antman E. M., Prasugrel versus clopidogrel in patients with acute coronary syndromes New England Journal of Medicine 2007 357 20 2001 2015
17. Wallentin L., Becker R. C., Budaj A., Cannon C. P., Emanuelsson H., Held C., Horrow J., Husted S., James S., Katus H., Mahaffey K. W., Scirica B. M., Skene A., Steg P. G., Storey R. F., Harrington R. A., Ticagrelor versus clopidogrel in patients with acute coronary syndromes New England Journal of Medicine 2009 361 11 1045 1057
18. Bhatt D. L., Lincoff A. M., Gibson C. M., CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI The New England Journal of Medicine 2009 361 24 2381 2329
19. Harrington R. A., Stone G. W., McNulty S., Platelet inhibition with cangrelor in patients undergoing PCI The New England Journal of Medicine 2009 36 24 2318 2329
20. Testa L., Bhindi R., van Gaal W. J., What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of Prasugrel. International Journal of Medicine. In press
21. Jakubowski J. A., Winters K. J., Naganuma H., Wallentin L., Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile Cardiovascular Drug Reviews 2007 25 4 357 374
22. Hagihara K., Kurihara A., Kawai K., Kazui M., Takahashi M., Kawabata K., Farid N. A., Ikeda T., Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats Xenobiotica 2007 37 7 788 801
23. Smith R. L., Gillespie T. A., Rash T. J., Kurihara A., Farid N. A., Disposition and metabolic fate of prasugrel in mice, rats, and dogs Xenobiotica 2007 37 8 884 901
24. Niitsu Y., Sugidachi A., Ogawa T., Jakubowski J. A., Hashimoto M., Isobe T., Otsuguro K.-I., Asai F., Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species European Journal of Pharmacology 2008 579 13 276 282
25. Sugidachi A., Asai F., Yoneda K., Iwamura R., Ogawa T., Otsuguro K.-I., Koike H., Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type Gi-linked P2T antagonist, CS-747 British Journal of Pharmacology 2001 132 1 47 54
26. Frelinger A. L. III, Jakubowski J. A., Li Y. F., Barnard M. R., Fox M. L., Linden M. D., Sugidachi A., Winters K. J., Furman M. I., Michelson A. D., The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin Thrombosis and Haemostasis 2007 98 1 192 200
27. Frelinger A. L., Jakubowski J. A., Li Y., Barnard M. R., Linden M. D., Tarnow I., Fox M. L., Sugidachi A., Winters K. J., Furman M. I., Michelson A. D., The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities Journal of Thrombosis and Haemostasis 2008 6 2 359 365
28. Hasegawa M., Sugidachi A., Ogawa T., Isobe T., Jakubowski J. A., Asai F., Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (Prasugrel, LY640315), a novel P2Y12 receptor inhibitor Thrombosis and Haemostasis 2005 94 3 593 598
29. Van Giezen J. J. J., Humphries R. G., Preclinical and clinical studies with selective reversible direct P2Y 12 antagonists Seminars in Thrombosis and Hemostasis 2005 31 2 195 204
30. Tantry U. S., Bliden K. P., Gurbel P. A., AZD6140 Expert Opinion on Investigational Drugs 2007 16 2 225 229
31. Nassim M. A., Sanderson J. B., Clarke C., Investigation of the novel P2T receptor antagonist AR-C69931MX on ex vivo adenosine diphosphate-induced platelet aggregation and bleeding time in healthy volunteers Journal of the American College of Cardiology 1999 33 2, supplement A 255A
32. Ingall A. H., Dixon J., Bailey A., Coombs M. E., Cox D., McInally J. I., Hunt S. F., Kindon N. D., Teobald B. J., Willis P. A., Humphries R. G., Leff P., Clegg J. A., Smith J. A., Tomlinson W., Antagonists of the platelet P(2T) receptor: A novel approach to antithrombotic therapy Journal of Medicinal Chemistry 1999 42 2 213 220
33. Wallentin L., Varenhorst C., James S., Erlinge D., Braun O. O., Jakubowski J. A., Sugidachi A., Winters K. J., Siegbahn A., Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease European Heart Journal 2008 29 1 21 30
34. Wiviott S. D., Trenk D., Frelinger A. L., PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial Circulation 2007 116 2923 2932
35. Wiviott S. D., Antman E. M., Winters K. J., Weerakkody G., Murphy S. A., Behounek B. D., Carney R. J., Lazzam C., McKay R. G., McCabe C. H., Braunwald E., Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial Circulation 2005 111 25 3366 3373
36. Serebruany V. L., Midei M. G., Meilman H., Malinin A. I., Lowry D. R., Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: The subset from the JUMBO study Postgraduate Medical Journal 2006 82 968 404 410
37. Wiviott S. D., Braunwald E., McCabe C. H., TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes The New England Journal of Medicine 2007 357 2001 2015
38. Wiviott S. D., Braunwald E., McCabe C. H., Horvath I., Keltai M., Herrman J.-P. R., Van de Werf F., Downey W. E., Scirica B. M., Murphy S. A., Antman E. M., Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial The Lancet 2008 371 9621 1353 1363
39. Antman E. M., Wiviott S. D., Murphy S. A., Voitk J., Hasin Y., Widimsky P., Chandna H., Macias W., McCabe C. H., Braunwald E., Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention. A TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibitioN with prasugrel- thrombolysis in myocardial infarction) analysis Journal of the American College of Cardiology 2008 51 21 2028 2033
40. Wiviott S. D., Braunwald E., Angiolillo D. J., TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation. In press
41. Montalescot G., Wiviott S. D., Braunwald E., Murphy S. A., Gibson C. M., McCabe C. H., Antman E. M., Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial The Lancet 2009 373 9665 723 731
42. Mega J. L., Close S. L., Wiviott S. D., Shen L., Hockett R. D., Brandt J. T., Walker J. R., Antman E. M., Macias W. L., Braunwald E., Sabatine M. S., Cytochrome P450 genetic polymorphisms and the response to prasugrel relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 2009 119 19 2553 2560
43. Cannon C. P., Husted S., Harrington R. A., Scirica B. M., Emanuelsson H., Peters G., Storey R. F., Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome. primary results of the DISPERSE-2 trial Journal of the American College of Cardiology 2007 50 19 1844 1851
44. Subherwal S., Bach R. G., Chen A. Y., The CRUSADE bleeding score to assess baseline risk of major bleeding in non-ST-segment elevation myocardial infarction Journal of American College of Cardiology 2008 51 supplement A 806 809
45. Moscucci M., Fox K. A. A., Cannon C. P., Klein W., López-Sendn J., Montalescot G., White K., Goldberg R. J., Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) European Heart Journal 2003 24 20 1815 1823
46. Nikolsky E., Mehran R., Dangas G., Fahy M., Na Y., Pocock S. J., Lincoff A. M., Stone G. W., Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach European Heart Journal 2007 28 16 1936 1945
47. Mehta S. K., Frutkin A. D., Lindsey J. B., House J. A., Spertus J. A., Rao S. V., Ou F. -S., Roe M. T., Peterson E. D., Marso S. P., Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the national cardiovascular data registry Circulation: Cardiovascular Interventions 2009 2 3 222 229
48. Biondi Zoccai G., Lotrionte M., Abbate A., Is prasugrel superior to ticagrelor For the treatment of patients with acute coronary syndromes? evidence from a 32,893-patient adjusted indirect comparison meta-analysis Proceedings of the Cardiovascular Revascularization Therapy Conference February 2010 Washington, DC, USA